4//SEC Filing
Kalb Michael Wayne 4
Accession 0001161697-25-000418
CIK 0001369568other
Filed
Nov 23, 7:00 PM ET
Accepted
Nov 24, 8:08 PM ET
Size
13.8 KB
Accession
0001161697-25-000418
Insider Transaction Report
Form 4
Kalb Michael Wayne
Executive Vice President & CFO
Transactions
- Tax Payment
Common Stock, par value $0.001 per share
2025-11-21−2,485→ 8,606 total - Exercise/Conversion
Restricted Stock Units
2025-11-21−6,894→ 640,042 total→ Common Stock (6,894 underlying) - Exercise/Conversion
Common Stock, par value $0.001 per share
2025-11-21+6,894→ 11,091 total - Award
Options to purchase common stock
2025-11-20+131,536→ 607,235 totalExercise: $22.77Exp: 2032-11-20→ Common Stock (131,536 underlying) - Award
Restricted Stock Units
2025-11-20+39,701→ 646,936 total→ Common Stock (39,701 underlying)
Footnotes (6)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- [F2]Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.
- [F3]Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028.
- [F4]Shares of common stock will be delivered to the Reporting Person upon vesting.
- [F5]Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.
- [F6]Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.
Documents
Issuer
CATALYST PHARMACEUTICALS, INC.
CIK 0001369568
Entity typeother
Related Parties
1- filerCIK 0001678248
Filing Metadata
- Form type
- 4
- Filed
- Nov 23, 7:00 PM ET
- Accepted
- Nov 24, 8:08 PM ET
- Size
- 13.8 KB